Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PURVI KOTHARI MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1336280031
CMS profile
15061
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,287.71

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,661.01 8
Food and Beverage $576.70 23
Honoraria $50.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $1,614.18 12
Eli Lilly and Company $464.42 17
Novo Nordisk AS $136.66 1
Flexion Therapeutics, Inc. $50.00 1
GlaxoSmithKline, LLC. $22.45 1

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PURVI KOTHARI MEHRA

NPI 1336280031 · CMS profile ID 15061

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $2,287.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $22.4507/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670915843 CMS
Eli Lilly and Company $8.3506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709012135 CMS
Eli Lilly and Company $4.6406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709013675 CMS
Eli Lilly and Company $18.5606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014159 CMS
Eli Lilly and Company $3.3406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014515 CMS
Eli Lilly and Company $4.6406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014857 CMS
Eli Lilly and Company $25.9906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015171 CMS
Eli Lilly and Company $44.5506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015173 CMS
Eli Lilly and Company $18.5606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015175 CMS
Eli Lilly and Company $33.4106/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015337 CMS
Eli Lilly and Company $136.9806/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015339 CMS
Eli Lilly and Company $1.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016879 CMS
Eli Lilly and Company $4.4606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016881 CMS
Eli Lilly and Company $11.1406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016883 CMS
Eli Lilly and Company $1.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016885 CMS
Eli Lilly and Company $2.6006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017571 CMS
Eli Lilly and Company $6.5006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017573 CMS
Eli Lilly and Company $136.9806/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017575 CMS
Novo Nordisk AS $136.6606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544125 CMS
Merck Sharp & Dohme Corporation $13.9105/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804301 CMS
Merck Sharp & Dohme Corporation $30.8205/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804747 CMS
Merck Sharp & Dohme Corporation $78.4105/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695805031 CMS
Merck Sharp & Dohme Corporation $103.1305/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804299 CMS
Merck Sharp & Dohme Corporation $24.9905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804585 CMS
Merck Sharp & Dohme Corporation $247.0605/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804745 CMS
Merck Sharp & Dohme Corporation $50.0005/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804749 CMS
Merck Sharp & Dohme Corporation $81.1905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695805033 CMS
Merck Sharp & Dohme Corporation $209.0005/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804583 CMS
Merck Sharp & Dohme Corporation $247.0605/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804743 CMS
Merck Sharp & Dohme Corporation $502.3905/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804751 CMS
Merck Sharp & Dohme Corporation $26.2205/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695806407 CMS
Flexion Therapeutics, Inc. $50.0001/08/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705866853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,287.71 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Recipient $375.00 2
PY2022 Principal investigator $30,891.10 5
PY2021 Principal investigator $3,333,813.44 59
PY2020 Recipient $3,034.66 5
PY2020 Principal investigator $1,118,926.99 96
PY2019 Recipient $6,389.04 5
PY2019 Principal investigator $1,783,635.66 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

101 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $5,992.00 12/22/2020 Non-covered Recipient Entity
Artemis Inst For Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719487376
Principal investigator 1 Janssen Research & Development, LLC $5,992.00 12/22/2020 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787979137
Principal investigator 1 PFIZER INC. $22,627.81 12/16/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742899475
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,386.15 12/11/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 748986483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,796.98 12/10/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724480885
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,448.31 12/10/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102399
Principal investigator 1 PFIZER INC. $27,461.84 12/03/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742899471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,796.98 11/24/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479655
Principal investigator 1 PFIZER INC. $144,388.79 11/21/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $245.26 11/19/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,661.85 11/19/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 11/19/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 11/19/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479283
Principal investigator 1 Eli Lilly and Company $7,231.00 11/17/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 728730663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 11/11/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724478793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.00 11/11/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724478799
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,385.91 11/11/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102391
Principal investigator 1 PFIZER INC. $1,057.66 11/09/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855625
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,385.91 11/05/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102387
Principal investigator 1 Eli Lilly and Company $21,226.00 10/27/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 728730659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,716.59 10/22/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724477909
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,704.59 10/22/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102377
Principal investigator 1 PFIZER INC. $1,586.49 10/19/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,205.89 10/15/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724477319
Principal investigator 1 PFIZER INC. $7,089.00 10/02/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854937
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 10/01/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 740742241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,507.00 10/01/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724476339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,056.00 10/01/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724476341
Principal investigator 1 Eli Lilly and Company $38,921.00 09/29/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 728730655
Principal investigator 1 Novo Nordisk AS $366.75 09/24/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439327
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,587.69 09/23/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102369
Principal investigator 1 PFIZER INC. $528.83 09/22/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,074.42 09/17/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724475359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,025.31 09/17/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724475365
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,926.66 09/17/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102367
Principal investigator 1 PFIZER INC. $528.83 09/16/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855291
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,587.69 09/03/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102363
Principal investigator 1 PFIZER INC. $1,586.49 08/31/2020 Non-covered Recipient Entity
Artemis Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855555
Principal investigator 1 Novo Nordisk AS $1,552.78 08/27/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439325
Recipient Eli Lilly and Company $827.96 08/26/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 728722429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,923.32 08/26/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724474203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,218.09 08/26/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724474211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,829.00 08/20/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724473719
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,744.09 08/20/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102357
Principal investigator 1 Eli Lilly and Company $2.00 08/14/2020 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728739575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,112.66 08/13/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724473369
Principal investigator 1 Eli Lilly and Company $114,522.00 08/03/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728731327
Recipient Eli Lilly and Company $145.50 07/31/2020 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 728722973
Recipient Eli Lilly and Company $87.00 07/31/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728723453
Principal investigator 1 Novo Nordisk AS $1,519.87 07/30/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57,669.16 07/29/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724472681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54,869.09 07/29/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724472683
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,652.10 07/23/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,254.71 07/16/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724470767
Principal investigator 1 Merck Sharp & Dohme Corporation $2,320.00 07/07/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 740742213
Recipient Eli Lilly Export S.A. Puerto Rico Branch $827.96 06/25/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 728723457
Recipient Eli Lilly and Company $1,146.24 06/25/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 728722425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,326.00 06/24/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724468993
Principal investigator 1 Novo Nordisk AS $859.78 06/23/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,161.83 06/18/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724467723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,802.13 06/18/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724467729
Principal investigator 1 Novo Nordisk AS $333.85 05/28/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439307
Principal investigator 1 Novo Nordisk AS $144.09 05/27/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43,294.41 05/27/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724465759
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,558.15 05/21/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,053.54 05/14/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724463797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,647.82 05/07/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724463405
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,589.39 04/29/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102343
Principal investigator 1 Novo Nordisk AS $1,742.06 04/23/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,737.86 04/22/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724461927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,888.00 04/22/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724461933
Principal investigator 1 Novo Nordisk AS $2.99 04/20/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439313
Principal investigator 1 Novo Nordisk AS $23.06 04/20/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,105.97 04/01/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724459757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,117.40 03/26/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724459185
Principal investigator 1 Novo Nordisk AS $685.40 03/24/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439303
Principal investigator 1 Eli Lilly and Company $2,716.20 03/18/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728732289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,311.62 03/12/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724457719
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,940.00 03/12/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,614.44 03/05/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724456917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,415.77 03/05/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724456923
Principal investigator 1 Novo Nordisk AS $1,623.93 02/25/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439299
Principal investigator 1 Novo Nordisk AS $550.00 02/25/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439301
Principal investigator 1 Eli Lilly and Company $15.27 02/20/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 728731009
Principal investigator 1 Merck Sharp & Dohme Corporation $6,496.00 02/18/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 740742211
Principal investigator 1 Novo Nordisk AS $2.99 02/14/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439309
Principal investigator 1 Novo Nordisk AS $23.06 02/14/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,959.79 02/13/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724454611
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,350.06 02/11/2020 Non-covered Recipient Entity
Artemis Institute For Clinical Research - San Diego
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod No dispute reported 06/30/2026 736758871
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,780.50 02/06/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102317
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,000.00 01/30/2020 Non-covered Recipient Entity
Artemis Institute For Clinical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 713676661
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 01/28/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 740742207
Principal investigator 1 Merck Sharp & Dohme Corporation $2,680.00 01/28/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 740742209
Principal investigator 1 Novo Nordisk AS $1,211.06 01/28/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439297
Principal investigator 1 Novo Nordisk AS $23.06 01/28/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 742439317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,626.59 01/28/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724453215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,650.12 01/22/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724451911
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,250.50 01/17/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102311
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,056.50 01/17/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 740102313
Principal investigator 1 Eli Lilly and Company $7,634.69 01/08/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 728731319
Principal investigator 1 Eli Lilly and Company $140,998.56 01/07/2020 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 728732285